Publications by authors named "J M Guy"
Objective: Pharmacologic thrombolytic treatment for acute ischemic stroke has primarily been managed by intravenous alteplase. Tenecteplase is a variant that has been shown to be non-inferior to alteplase in clinical trials. In this study, we present a real-world assessment of patient outcomes with the facility-wide transition to the use of tenecteplase versus altepase for acute ischemic stroke in a large system of community hospitals in the United States.
View Article and Find Full Text PDFArticle Synopsis
- Preterm birth (PTB) is a major cause of complications in newborns, and identifying women at risk for spontaneous preterm labor (PTL) is difficult due to the lack of reliable diagnostic tools.
- The study investigated the link between specific maternal lymphocyte subpopulations and the likelihood of giving birth within 7 days for women hospitalized with PTL between 24 and 34 weeks of pregnancy.
- Results indicated that higher levels of certain lymphocyte markers were associated with a higher likelihood of delivering soon, allowing for the potential identification of high-risk women and possibly reducing unnecessary hospital admissions and related healthcare costs if confirmed in future research.
Purpose: Cluster of differentiation 40 (CD40) is expressed on B-cell acute lymphoblastic leukemia (B-ALL) cases. However, the effect of CD40 activation on B-ALL cells has never been tested in vivo.
Experimental Design: The aim of our preclinical study was to investigate the therapeutic potential of a CD40 agonist in the treatment of B-ALL using patient-derived xenograft mouse models.
Objective: To assess the feasibility of a pilot pharmacogenomics concierge service that incorporates student practice-based learning opportunities and a survey to determine the patients' interest and willingness to pay.
Methods: Participants in the pilot study (n = 34) completed a survey to determine their willingness to pay for concierge services. Six participants indicating the highest level of interest were selected to participate in the program free of charge.
Dexamethasone Dose for COVID-19 in a Large U.S. Hospital Network From April 2020 to May 2023.
Pharmacoepidemiol Drug Saf
October 2024
Purpose: While potential harm from high doses of systemic dexamethasone for clinical management of COVID-19 is an important concern, little is known about real world dexamethasone dosing in patients hospitalized with COVID-19 in the United States.
Methods: Descriptive study to assess dexamethasone daily dose in adults with COVID-19 in a large US hospital network, overall and by respiratory support requirements, extracted using semi- structured nursing notes.
Results: Of 332 430 hospitalizations with a COVID-19 diagnosis, 201 637 (60.